{
    "ticker": "BOLT",
    "info": {
        "address1": "900 Chesapeake Drive",
        "city": "Redwood City",
        "state": "CA",
        "zip": "94063",
        "country": "United States",
        "phone": "650 665 9295",
        "website": "https://www.boltbio.com",
        "industry": "Biotechnology",
        "industryKey": "biotechnology",
        "industryDisp": "Biotechnology",
        "sector": "Healthcare",
        "sectorKey": "healthcare",
        "sectorDisp": "Healthcare",
        "longBusinessSummary": "Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.",
        "fullTimeEmployees": 100,
        "companyOfficers": [
            {
                "maxAge": 1,
                "name": "Mr. William P. Quinn",
                "age": 52,
                "title": "CEO, CFO, President, Secretary & Director",
                "yearBorn": 1971,
                "fiscalYear": 2023,
                "totalPay": 610800,
                "exercisedValue": 0,
                "unexercisedValue": 0
            },
            {
                "maxAge": 1,
                "name": "Mr. Grant  Yonehiro C.F.A., M.B.A.",
                "age": 59,
                "title": "Chief Operating Officer",
                "yearBorn": 1964,
                "fiscalYear": 2023,
                "totalPay": 564650,
                "exercisedValue": 0,
                "unexercisedValue": 0
            },
            {
                "maxAge": 1,
                "name": "Ms. Sarah  Nemec",
                "age": 47,
                "title": "VP of Finance & Principal Accounting Officer",
                "yearBorn": 1976,
                "fiscalYear": 2023,
                "exercisedValue": 0,
                "unexercisedValue": 0
            },
            {
                "maxAge": 1,
                "name": "Mr. Wesley  Burwell",
                "title": "VP & Head of Human Resources",
                "fiscalYear": 2023,
                "exercisedValue": 0,
                "unexercisedValue": 0
            },
            {
                "maxAge": 1,
                "name": "Dr. Nathan  Ihle Ph.D.",
                "title": "Senior Vice President of Pharmaceutical Operations",
                "fiscalYear": 2023,
                "exercisedValue": 0,
                "unexercisedValue": 0
            },
            {
                "maxAge": 1,
                "name": "Dr. Dawn  Colburn BCOP, Pharm.D.",
                "title": "Senior Vice President of Clinical Development",
                "fiscalYear": 2023,
                "exercisedValue": 0,
                "unexercisedValue": 0
            },
            {
                "maxAge": 1,
                "name": "Dr. Michael N. Alonso Ph.D.",
                "title": "Senior Vice President of Research",
                "fiscalYear": 2023,
                "exercisedValue": 0,
                "unexercisedValue": 0
            }
        ],
        "auditRisk": 8,
        "boardRisk": 9,
        "compensationRisk": 9,
        "shareHolderRightsRisk": 8,
        "overallRisk": 9,
        "governanceEpochDate": 1730073600,
        "compensationAsOfEpochDate": 1703980800,
        "maxAge": 86400,
        "priceHint": 4,
        "previousClose": 0.6699,
        "open": 0.6705,
        "dayLow": 0.6363,
        "dayHigh": 0.687,
        "regularMarketPreviousClose": 0.6699,
        "regularMarketOpen": 0.6705,
        "regularMarketDayLow": 0.6363,
        "regularMarketDayHigh": 0.687,
        "beta": 0.929,
        "forwardPE": -0.5036719,
        "volume": 123784,
        "regularMarketVolume": 123784,
        "averageVolume": 176664,
        "averageVolume10days": 177190,
        "averageDailyVolume10Day": 177190,
        "bid": 0.6194,
        "ask": 0.6797,
        "bidSize": 100,
        "askSize": 100,
        "marketCap": 25534568,
        "fiftyTwoWeekLow": 0.545,
        "fiftyTwoWeekHigh": 1.56,
        "priceToSalesTrailing12Months": 2.2868142,
        "fiftyDayAverage": 0.64694,
        "twoHundredDayAverage": 0.899555,
        "currency": "USD",
        "enterpriseValue": -30136656,
        "floatShares": 25038983,
        "sharesOutstanding": 38264800,
        "sharesShort": 119446,
        "sharesShortPriorMonth": 195596,
        "sharesShortPreviousMonthDate": 1726185600,
        "dateShortInterest": 1728950400,
        "sharesPercentSharesOut": 0.0031,
        "heldPercentInsiders": 0.03457,
        "heldPercentInstitutions": 0.59887004,
        "shortRatio": 0.86,
        "shortPercentOfFloat": 0.0039,
        "impliedSharesOutstanding": 39606900,
        "bookValue": 2.244,
        "priceToBook": 0.28729945,
        "lastFiscalYearEnd": 1703980800,
        "nextFiscalYearEnd": 1735603200,
        "mostRecentQuarter": 1719705600,
        "netIncomeToCommon": -66166000,
        "trailingEps": -1.68,
        "forwardEps": -1.28,
        "enterpriseToRevenue": -2.699,
        "enterpriseToEbitda": 0.417,
        "52WeekChange": -0.32999998,
        "SandP52WeekChange": 0.3763833,
        "exchange": "NMS",
        "quoteType": "EQUITY",
        "symbol": "BOLT",
        "underlyingSymbol": "BOLT",
        "shortName": "Bolt Biotherapeutics, Inc.",
        "longName": "Bolt Biotherapeutics, Inc.",
        "firstTradeDateEpochUtc": 1612535400,
        "timeZoneFullName": "America/New_York",
        "timeZoneShortName": "EDT",
        "uuid": "dff93495-0732-3bf9-90c2-03f27dac1fe3",
        "messageBoardId": "finmb_297390520",
        "gmtOffSetMilliseconds": -14400000,
        "currentPrice": 0.6447,
        "targetHighPrice": 2.0,
        "targetLowPrice": 1.5,
        "targetMeanPrice": 1.75,
        "targetMedianPrice": 1.75,
        "recommendationMean": 3.0,
        "recommendationKey": "hold",
        "numberOfAnalystOpinions": 2,
        "totalCash": 73697000,
        "totalCashPerShare": 1.926,
        "ebitda": -72229000,
        "totalDebt": 18891000,
        "quickRatio": 4.128,
        "currentRatio": 4.281,
        "totalRevenue": 11166000,
        "debtToEquity": 22.002,
        "revenuePerShare": 0.294,
        "returnOnAssets": -0.29406,
        "returnOnEquity": -0.58042,
        "freeCashflow": -33362624,
        "operatingCashflow": -63907000,
        "revenueGrowth": -0.11,
        "operatingMargins": -14.92706,
        "financialCurrency": "USD",
        "trailingPegRatio": null
    }
}